These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 20970606)
1. Changes in magnesium and potassium homeostasis after conversion from a calcineurin inhibitor regimen to an mTOR inhibitor-based regimen. Sánchez-Fructuoso AI; Santín Cantero JM; Pérez Flores I; Valero San Cecilio R; Calvo Romero N; Vilalta Casas R Transplant Proc; 2010 Oct; 42(8):3047-9. PubMed ID: 20970606 [TBL] [Abstract][Full Text] [Related]
2. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy. Kacar S; Gurkan A; Karaca C; Varılsuha C; Tilif S Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806 [TBL] [Abstract][Full Text] [Related]
3. Clinical insights for cancer outcomes in renal transplant patients. Alberú J Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450 [TBL] [Abstract][Full Text] [Related]
4. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation? Zeier M; Van Der Giet M Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495 [TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607 [TBL] [Abstract][Full Text] [Related]
6. Long-term maintenance therapy with calcineurin inhibitors: an update. Campistol JM Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445 [TBL] [Abstract][Full Text] [Related]
7. Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin. Paoletti E; Cannella G Transplant Proc; 2010 Nov; 42(9 Suppl):S41-3. PubMed ID: 21095451 [TBL] [Abstract][Full Text] [Related]
9. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient. Signorell J; Hunziker T; Martinelli M; Koestner SC; Mohacsi PJ Transplant Proc; 2010 Nov; 42(9):3871-5. PubMed ID: 21094874 [TBL] [Abstract][Full Text] [Related]
10. Timing of conversion to mammalian target of rapamycin inhibitors is crucial in liver transplant recipients with impaired renal function at transplantation. Schleicher C; Palmes D; Utech M; Bonrath E; Senninger N; Schmidt H; Wolters H Transplant Proc; 2010 Sep; 42(7):2572-5. PubMed ID: 20832546 [TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? Rostaing L; Kamar N J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724 [TBL] [Abstract][Full Text] [Related]
12. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years. Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Molina MG; Hernandez D Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551 [TBL] [Abstract][Full Text] [Related]
13. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease. Wüthrich RP; Kistler AD; Serra AL Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452 [TBL] [Abstract][Full Text] [Related]
14. Number of peripheral blood regulatory T cells and lymphocyte activation at 3 months after conversion to mTOR inhibitor therapy. San Segundo D; Fernández-Fresnedo G; Gago M; Beares I; Ruiz-Criado J; González M; Ruiz JC; Gómez-Alamillo C; Arias M; López-Hoyos M Transplant Proc; 2010 Oct; 42(8):2871-3. PubMed ID: 20970555 [TBL] [Abstract][Full Text] [Related]
15. Progression of graft fibrosis under mammalian target of rapamycin inhibitor-based regimen. Yilmaz M; Nart A; Sen S; Tasli F; Uslu A; Hur E; Ozkahya M; Hoscoskun C; Toz H Nephrology (Carlton); 2010 Sep; 15(6):653-8. PubMed ID: 20883287 [TBL] [Abstract][Full Text] [Related]
16. Indications and effectiveness of the mammalian target of rapamycin in liver transplantation. Sanchez Antolín G; Garcia Pajares F; Lorenzo Pelayo S; Herranz Bachiller MT; Almohalla C; Velicia R; Caro Paton A Transplant Proc; 2011 Apr; 43(3):714-7. PubMed ID: 21486581 [TBL] [Abstract][Full Text] [Related]
17. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors. Nashan B Transpl Int; 2004 Jul; 17(6):279-85. PubMed ID: 15221123 [TBL] [Abstract][Full Text] [Related]
19. Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression. Heering PJ; Kurschat C; Vo DT; Klein-Vehne N; Fehsel K; Ivens K Clin Transplant; 2004 Apr; 18(2):186-92. PubMed ID: 15016134 [TBL] [Abstract][Full Text] [Related]
20. Management of chronic allograft dysfunction by switch over to rapamycin. Sundaram V; Abraham G; Fathima N; Sundaram V; Reddy YN; Mathew M; Sathiah V Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):37-42. PubMed ID: 20061690 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]